fusion by insertion of 21q into 12p has been previously described, 6 we are the first to report the opposite phenomenon, namely insertion of 12p into 21q, producing the same result.
Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable 
TO THE EDITOR
Acute myeloid leukemia (AML) is a clonal disease characterized by a myriad of genetic abnormalities of a malignant clone, including translocations involving oncogenes and transcription factors, alterations to growth factor receptors and activation of signal transduction pathways. [1] [2] [3] Akt or protein kinase B (Akt/PKB), a serine/threonine protein kinase, has emerged as a crucial regulator of widely divergent cellular processes, including apoptosis, proliferation, differentiation and metabolism. Phosphorylation at the threonine residue-308 (pThr308) and serine residue-473 (pSer473) occurs in response to diverse stimuli, such as hormones, growth factors and extracellular matrix components. Phosphorylation of Thr308 is dependent on the products of phosphoinositide 3-kinase (PI-3K). 4 The mechanism of Ser473 phosphorylation remains less clear. Recent evidences indicate that constitutive activation of Akt/ PKB is frequently observed in various cancers. [5] [6] [7] [8] The level of Akt/ PKB expression and kinase activity are often associated with the degree of differentiation, hormone dependency, aggressive characteristics of tumor cells or prognosis. [7] [8] However, the constitutive phosphorylation of Akt/PKB and its clinical significance in AML have not been evaluated yet. Here, we investigated the state of constitutive phosphorylation of Akt/PKB in AML cells, and analyze its significance as a prognostic variable.
In all, 61 adults with de novo AML (M0, 2; M1, 7; M2, 23; M3, 2; M4, 18; M5, 8; M6, 1) who had not received treatment were included in the study. A total of 53 patients received induction chemotherapy comprising conventional-dose cytarabine and idarubicin. Two patients with M3 received all-trans retinoic acid and idarubicin. All patients achieving complete remission (CR) then received two courses of MEC consolidation therapy consisting of intermediate-dose cytarabine, mitoxantrone and VP-16. The relapsed patients also received MEC chemotherapy. The expression of total Akt/PKB and phosphorylation at the Thr308 and Ser473 residue in the isolated AML cells were evaluated by Western blot analysis using antibodies against total Akt/PKB, pThr308 and pSer473 (New England Biolabs, Beverly, MA, USA), respectively ( Figure 1 ). The expression of total Akt/PKB protein was present in 49 (80.3%) of the 61 untreated AML cases. The constitutive phosphorylation of Ser473 and Thr308 were both observed in 44 cases (72.1%). The simultaneous phosphorylation of Ser473 and Thr308 was exhibited in 43 (87.8%) out of the total Akt/PKB-positive AML cases. In contrast to AML cells, none of the total Akt/PKB, pSer473 or pThr308 was exhibited in the CD34-positive bone marrow cells obtained from seven healthy volunteers. Neither the total Akt/PKB, pSer473 nor pThr308 were significantly associated with age, sex, white blood cell count, lactic dehydrogenase level, FAB subtype and cytogeneic abnormality. We compared the PI-3K activity between seven AML cases expressing the pS473 and seven without. The constitutive expression of the p85kDa regulatory/adaptor subunit of PI-3K was observed in all of the pSer473-positive AML cases, but was observed in none of pSer473-negative AML cases (Figure 2a) . To demonstrate that the constitutive phosphorylation of the Akt/PKB in AML cells was PI-3K dependent, we incubated the AML cells obtained from the seven representative AML cases with 50 mM of the PI-3K inhibitor, LY294002 (Calbiochem, San Diego, CA, USA). The expression of the total Akt/PKB was unchanged during the treatment with LY294002. However, blocking the PI-3K activity, by culturing AML cells for 30 min in the presence of LY294002, significantly F albeit not completely F abrogated the phosphorylation of the Ser473 and Thr308 (Figure 2b ). The degree of abrogation of phosphorylation by LY294002 was greater in the Thr308 compared to that in the Ser473. Although PI-3K may not be the sole mediator of constitutive Akt/PKB phosphorylation in AMLcells, these data demonstrate that PI-3K is involved in the constitutive phosphorylation of the Akt/PKB in AML cells.
Of the 61 patients analyzed for Akt/PKB expression, 55 receiving the antileukemic chemotherapy were analyzed as a prognostic study. The CR rates were not different in relation to the expression of the total Akt/PKB (75.0% for total Akt/PKB-positive vs 81.8% for total Akt/PKB-negative) and phosphorylation of Ser473 (76.9% for pSer473 positive vs 75.0% for pSer473 negative). Disease-free survival (DFS) was not statistically different in relation to the expression of the total Akt/PKB or phosphorylation of Ser473 in the AML cells, although there was a trend toward a shorter DFS in the pSer473-positive patients compared to the pSer473-negative patients (median, 4 vs 10 months). There was a significant difference in the overall survival in relation to the total Akt/PKB expression ( Figure 3a) and pSer473 (Figure 3b ). The overall survival was significantly shorter in patients with constitutive pSer473 than in those without (median, 3 vs 13 months, P ¼ 0.031). The probability of survival at 12 months was 0.36 in the pSer473-positive AML and 0.71 in the pSer473-negative AML. Owing to the limited number of patients, the prognostic significance of the constitutive Akt/PKB phosphorylation of each of the three cytogenetical subgroups could not be analyzed individually. The overall survival of the pThr308-positive cases was also significantly shorter than that in the pThr308-negative cases. We have shown that the constitutive phosphorylation of Akt/PKB protein is a very frequent event in de novo AML, detecting over 70% of the AML cases evaluated. Cellular transformation, triggered by various tyrosine kinase oncoproteins, has been associated with the constitutive activation of Akt/PKB, 6 but involvement of these oncoproteins has not been demonstrated in AML, and cannot explain the high proportion of patients with constitutive Akt/PKB phosphorylation in this disease. In our study, the constitutive expression of the p85kDa regulatory/adaptor subunit of PI-3K was observed in the phosphorylated Akt/PKBpositive AML cases evaluated. In contrast, it was observed in none Western blot analysis demonstrated the constitutive phosphorylation of Ser473 and Thr308 residues in the total Akt/PKB-positive AML cases (lanes 3-10) , but not in the CD34-positive normal bone marrow cells (lanes 1-2) or the total Akt/PKB-negative AML cases (lane 11-12). HL60 cell lines were loaded to provide a standard curve. Correspondence of the phosphorylated Akt/PKB-negative AML. The finding that the phosphorylation of Akt/PKB protein was significantly abrogated by incubating AML cells with the PI-3K inhibitor suggests that most, but not all, constitutive Akt/PKB phosphorylation in AML results from the constitutive activation of the PI-3K pathway. The molecular mechanism for the constitutive PI-3K activation and Akt/PKB phosphorylaton in AML cells should be further evaluated. The possible contribution of the PI-3K-independent pathway to the constitutive phosphorylation of Akt/PKB also needs to be examined.
We have demonstrated that constitutive Akt/PKB phosphorylation was significantly associated with overall survival. The overall survival of patients with the pSer473 was significantly shorter than that of patients without. This study demonstrated the effect of Akt/ PKB phosphorylation in shortening overall survival without concomitantly reducing DFS. This discrepancy might be explained by the fact that the relapsed or refractory patients without pSer473 showed significantly longer survival than those with pSer473 (P ¼ 0.021). There was a trend for a higher second CR rate with salvage chemotherapy in patients without the pSer473 compared to those with the pSer473 expression (80.0 vs 37.5%). Although the mechanisms responsible for the constitutive phosphorylation of the Akt/PKB protein remain to be explained, the finding that the constitutive phosphorylation of the Akt/PKB was observed in a vast majority of AML cases may lend additional insight into the molecular pathogenesis of AML. In addition, the detection of the Akt/PKB phosphorylation may provide a new tool for identifying AML patients at high risk of an unfavorable outcome. 
